Feedback / Questions
Leqvio (inclisiran) - Novartis
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
Kesimpta (ofatumumab subcutaneous) - Novartis, Genmab
Kisqali (ribociclib) - Novartis
Scemblix (asciminib) - Novartis
https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed
Jul 21, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next